Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Amalgamated Bank

Amalgamated Bank lowered its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 3.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 72,701 shares of the life sciences company's stock after selling 2,650 shares during the quarter. Amalgamated Bank's holdings in Illumina were worth $5,768,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Capital World Investors raised its stake in Illumina by 408.6% in the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after buying an additional 14,481,232 shares in the last quarter. Brown Advisory Inc. raised its position in shares of Illumina by 54,220.9% during the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock worth $255,586,000 after acquiring an additional 1,909,118 shares in the last quarter. Norges Bank purchased a new stake in Illumina during the fourth quarter worth approximately $228,714,000. Bessemer Group Inc. boosted its holdings in Illumina by 32,837.5% in the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after purchasing an additional 1,344,038 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Illumina by 2,057.5% in the first quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock valued at $73,174,000 after purchasing an additional 879,533 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Up 0.1%

Shares of NASDAQ ILMN traded up $0.10 during midday trading on Friday, reaching $100.44. 1,423,748 shares of the stock were exchanged, compared to its average volume of 2,144,110. The stock has a 50 day moving average price of $84.58 and a 200-day moving average price of $98.02. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $15.90 billion, a P/E ratio of -16.55, a P/E/G ratio of 1.97 and a beta of 1.36. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. Illumina's revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.98 earnings per share. Equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Illumina news, CFO Ankur Dhingra purchased 6,100 shares of the firm's stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $81.21 per share, with a total value of $495,381.00. Following the purchase, the chief financial officer owned 24,906 shares in the company, valued at approximately $2,022,616.26. This represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 2.60% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Guggenheim dropped their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Morgan Stanley cut their target price on Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. JPMorgan Chase & Co. decreased their target price on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Citigroup cut their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. Finally, Royal Bank Of Canada decreased their price objective on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Illumina presently has an average rating of "Moderate Buy" and a consensus price target of $127.39.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.